Eli Lilly launches oral GLP-1 therapy; stock surges past $1,200 on blockbuster earnings and market expansion
Eli Lilly's oral GLP-1 launch and strong earnings drive stock gains amid expanded obesity drug competition and Medicare coverage discussions.
Blockonomi · +7 outlets
Novo Nordisk's Wegovy oral weight loss pill now available in UK; Medicare and MASH expansion underway
Novo Nordisk expands Wegovy reach into UK market and pursues US Medicare coverage while developing MASH indication.
AD HOC NEWS · +14 outlets
Supreme Court deals major blow to Big Pharma over Biden-era Medicare drug pricing law
Court ruling upholds Medicare negotiation authority, limiting pharma industry's legal challenges to drug price controls.
MSN · +8 outlets
Vera Therapeutics stock rallies on imminent FDA decision for kidney disease drug atacicept
Vera's lead candidate atacicept faces FDA review for rare kidney disease (IgA nephropathy), driving significant investor interest ahead of decision.
finance.biggo.com · +9 outlets
Compass Pharmaceutics achieves primary endpoint in Phase 3 treatment-resistant depression trial; stock rises 23% premarket
Compass hits primary goal in large Phase 3 depression study, potentially supporting accelerated regulatory pathway.
Stocktwits · +14 outlets
Viking Therapeutics faces uphill battle in GLP-1 race; Foundayo oral formulation models $71M debut quarter US sales
Multiple companies compete in high-stakes oral GLP-1 market; analysts project significant early sales but intense competition ahead.
foreignpolicyjournal.com · +1 outlets
Trump administration warns pharma companies to cut drug prices or face punitive action
Trump administration escalates pricing pressure on pharmaceutical industry amid broader cost control agenda.
MSN · +8 outlets
Sarepta seeks permanent FDA approval for two Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53
Sarepta pursues full NDA acceptance for both exon-skipping dystrophin therapies following prior conditional approvals.
Sarepta Therapeutics · +3 outlets
Rocket Pharmaceuticals' gene therapy for rare childhood immune disease wins FDA approval; stock jumps 10% premarket
Rocket achieves FDA approval for ex vivo gene therapy treating adenosine deaminase deficiency.
Stocktwits
Invivyd's COVID treatment PEMGARDA faces EUA termination by end of 2027 as HHS winds down emergency declaration
FDA notified Invivyd that PEMGARDA's COVID-19 emergency use authorization will end in 2027 following wind-down of the HHS emergency declaration.
Stock Titan · +1 outlets
Pharvaris wins FDA review for deucrictibant, first oral on-demand HAE attack treatment
Pharvaris advances first oral kallikrein inhibitor for hereditary angioedema, addressing unmet acute attack treatment need.
Quiver Quantitative · +5 outlets
Travelers Therapeutics wins approval for rare kidney disease drug; Viridian FDA approves Lumvoa for thyroid eye disease
Two rare disease wins signal continued regulatory momentum for specialized immunology and ophthalmology therapies.
Stocktwits · +1 outlets
Drug pricing pressure impacts GSK and global pharma stocks; Medicare GLP-1 access expands
Regulatory pricing pressure and benefit changes reshape pharma sector dynamics and market access.
simplywall.st · +4 outlets
Ascletis files dual US INDs for ultra-long-acting obesity therapies targeting multiple incretin receptors
Ascletis advances next-generation obesity treatments designed for less frequent dosing than current GLP-1 drugs.
BioPharma APAC
Oral obesity therapies market projected to reach $6.31B by 2030 at 9.9% CAGR
Market analysis reflects sustained growth in oral GLP-1 and alternative obesity drug formulations.
EIN News
GRAIL valued 5% overvalued following trial miss and mounting class action lawsuits
Guardant's blood cancer screening test faces clinical setback and litigation, raising valuation concerns.
simplywall.st · +1 outlets
Organogenesis wins FDA review for ReNu, knee osteoarthritis treatment
Organogenesis advances regenerative medicine approach to joint disease, expanding beyond current surgical options.
Stock Titan · +2 outlets
Positive Phase 2 results reported for new oral GLP-1 obesity therapy
Additional oral GLP-1 candidate demonstrates clinical efficacy, intensifying competitive landscape.
Medscape